PeptideStack
5.2kquestions
20kanswers
220users

How do I check that two QST lots of tirzepatide agree on content assay?

Asked 13 Jun 2025Modified 10 months agoViewed 11k times
23

Concretely: QST · tirzepatide.

I have two candidate explanations and no way to distinguish them.

The same procedure has worked without incident several times previously, which argues against technique.

Is this recoverable, and how would I tell?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
content-assay
content-assay

Quantified content: how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard. A separate test…

476 questions
vendor-vetting
vendor-vetting

Evaluating a supplier on evidence rather than reputation: testing history across batches, whether certificates are batch-specific, how failures…

454 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
shareeditfollowflag
SH
askedseven_day_half31k13813 Jun 2025
Add the gradient and the column if you have them — half the answer depends on those. – area_percent 42 days ago
2Same question came up on a different supplier and the answer was entirely about the method. – w_okoye 3 months ago
add a comment

5 Answers

Accepted answer first, then by votes
34

Accepted answer

The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

Worth being precise here: if the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
GA
answered · acceptedgrainne_ahearn50k3810 Oct 2025
Do you have the chromatogram for this, or just the summary figure? – petra_hovland 6 months ago
2Confirming from the other direction: I ignored the method section once and paid for it. – RP_C18 8 months ago
add a comment
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
41

Worth being precise here: batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.

Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

On the detail: the statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

Assume segregation is possible, and design your sampling to catch it if it exists.

shareimprove this answerflag
TW
answeredtare_weight60k1485 Jul 2025
27

The part that matters: the single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
JW
answeredj_wierzbicki69k14816 Jul 2025
12

Thermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.

Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

shareimprove this answerflag
KA
answeredkwn_analytical147k35818 Aug 2025
Which wavelength was the purity integrated at? It changes the number more than people think. – Dr_Ravi_Selvarajah 8 months ago
I would gently push back on the second point — inter-laboratory spread is wider than stated. – ivo_paunovic 6 months ago
add a comment
-3

In practice, two vials tested from a lot of ten is very different from two vials tested from a lot of ten thousand, and most certificates do not state the lot size.

A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.

shareimprove this answerflag
TM
answeredtobias_maartens171k35824 Jun 2025
3Thank you — this is the answer I was looking for. – marta_okonkwo 3 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.